ArticleFrontiers in pharmacology2025
A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system.
Jingjing Huang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it